Jasper Therapeutics Inc-A 2024年度报告

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes…No7 The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2024 (the last business day of the registrant’smost recently completed second fiscal quarter) was approximately $281.0 million based on the closing price of the registrant’s common stock on June 30, 2024 of $22.70 per share,as reported by the Nasdaq Capital Market. TABLE OF CONTENTS PART I Item 1.Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1Item 1A.Risk Factors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23Item 1B.Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80Item 1C.Cybersecurity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80Item 2.Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80Item 3.Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .81Item 4.Mine Safety Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .81 PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and IssuerPurchases of Equity Securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82Item 6.[Reserved] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82Item 7.Management’s Discussion and Analysis of Financial Condition and Results ofOperations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82Item 7A.Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . .95Item 8.Financial Statements and Supplementary Data. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .F-1Item 9.Changes in and Disagreements With Accountants on Accounting and FinancialDisclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96Item 9A.Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96Item 9B.Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections . . . . . . . . . . . . . . . . . .96 PART III Item 10.Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . .97Item 11.Executive Compensation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .110Item 12.Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .120Item 13.Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . .123Item 14.Principal Accountant Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .125 PART IV Item 15.Exhibit and Financial Statement Schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .126Item 16.Form 10-K Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .128 JASPER THERAPEUTICS, INC. As used in this Annual Report on Form 10-K, unless the context requires otherwise, references to the “Company”,“Jasper”, “we”, “us”, “our”, and similar terms refer to Jasper Therapeutics, Inc., a Delaware corporation formerlyknown as Amplitude Healthcare Acquisition Corporation (“AMHC”), and its consolidated subsidiary. References to“Old Jasper” refer to the private Delaware corporation that is now our wholly-owned subsidiary and named Jasper TxCorp. (formerly known as Jasper Therapeutics, Inc.). On September 24, 2021, we consummated the previously announced Business Combination (as defined below)(pursuant to the Business Combination Agreement, dated May 5, 2021, by and among AMHC, Ample Merger Sub,Inc. (“Merger Sub”) and Old Jasper). Pursuant to the terms of the Business Combination Agreement, a businesscombination (herein referred to as the “Business Combination” or “Reverse Recapitalization” for accounting purposes)between AMHC and Old Jasper was effected through the merger of Merger Sub w